Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ZBH 
Zimmer Biomet Holdings Inc (ZBH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: ZBH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
29 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $107.5
1 Year Target Price $107.5
| 5 | Strong Buy |
| 6 | Buy |
| 16 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.72% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 18.56B USD | Price to earnings Ratio 20.84 | 1Y Target Price 107.5 |
Price to earnings Ratio 20.84 | 1Y Target Price 107.5 | ||
Volume (30-day avg) 29 | Beta 0.72 | 52 Weeks Range 88.99 - 115.64 | Updated Date 07/12/2025 |
52 Weeks Range 88.99 - 115.64 | Updated Date 07/12/2025 | ||
Dividends yield (FY) 1.05% | Basic EPS (TTM) 4.5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.87% | Operating Margin (TTM) 17.85% |
Management Effectiveness
Return on Assets (TTM) 4.42% | Return on Equity (TTM) 7.32% |
Valuation
Trailing PE 20.84 | Forward PE 11.79 | Enterprise Value 24347953978 | Price to Sales(TTM) 2.41 |
Enterprise Value 24347953978 | Price to Sales(TTM) 2.41 | ||
Enterprise Value to Revenue 3.16 | Enterprise Value to EBITDA 10.6 | Shares Outstanding 197848000 | Shares Floating 197254350 |
Shares Outstanding 197848000 | Shares Floating 197254350 | ||
Percent Insiders 0.15 | Percent Institutions 95.36 |
Upturn AI SWOT
Zimmer Biomet Holdings Inc
Company Overview
History and Background
Zimmer Biomet Holdings, Inc. was formed in 2015 through the merger of Zimmer Holdings and Biomet. Zimmer was founded in 1927. The combined company develops, manufactures, and markets orthopedic reconstructive products, sports medicine, biologics, extremities and trauma products, office-based technologies, spine, bone healing, craniomaxillofacial and thoracic products, and related surgical products.
Core Business Areas
- Americas: Includes the United States, Canada, and Latin America. Largest revenue segment.
- Europe, Middle East and Africa (EMEA): Includes sales to Western and Eastern Europe, the Middle East, and Africa.
- Asia Pacific: Includes Japan, China, Australia, and other Asian countries.
Leadership and Structure
As of October 2024, Ivan Tornos is the President and CEO. The company operates under a board of directors and has a structured organizational chart with various functional departments like R&D, sales, marketing, finance, and operations.
Top Products and Market Share
Key Offerings
- Knee Implants: Zimmer Biomet is a leading provider of knee replacement systems. Competitors include Stryker, Johnson & Johnson (DePuy Synthes), and Smith & Nephew. Market share is significant, estimated to be in the range of 30-35% of global knee implant market. Sales drive approximately 25-30% of total company revenue.
- Hip Implants: Zimmer Biomet also offers a wide range of hip replacement systems. Competitors in hip replacement are Stryker, Johnson & Johnson (DePuy Synthes), and Smith & Nephew. The Hip implants business contributes approximately 15-20% to the overall revenue.
- Sports Medicine: Products for arthroscopic and minimally invasive surgical procedures. Competitors include Arthrex, Smith & Nephew and Stryker. This segment accounts for approximately 10-15% of total revenue.
- Spine: Spinal fusion and non-fusion systems. Competitors include Medtronic, Johnson & Johnson (DePuy Synthes), and NuVasive. It accounts for approximately 10% of total revenue.
Market Dynamics
Industry Overview
The orthopedic device industry is characterized by an aging population, increasing rates of obesity, and technological advancements like robotics and personalized implants. The industry faces regulatory hurdles and pricing pressures.
Positioning
Zimmer Biomet is one of the largest players in the orthopedic device market, holding a leading position in reconstructive implants. Its competitive advantage lies in its broad product portfolio, global presence, and established relationships with surgeons and hospitals.
Total Addressable Market (TAM)
The global orthopedic device market is estimated to be around $50 billion. Zimmer Biomet is well-positioned to capture a significant share of this market, especially with innovations and geographic expansion.
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Global distribution network
- Established brand reputation
- Strong R&D capabilities
- Extensive surgeon relationships
Weaknesses
- Integration challenges from merger
- Exposure to pricing pressures
- Product recalls and liability risks
- High debt levels
- Slower growth compared to some competitors
Opportunities
- Expanding into emerging markets
- Developing innovative technologies (robotics, personalized implants)
- Acquiring smaller, specialized companies
- Increasing demand due to aging population
- Strategic partnerships
Threats
- Intense competition
- Regulatory changes and approvals
- Economic downturns affecting healthcare spending
- Shifting reimbursement policies
- Material costs
Competitors and Market Share
Key Competitors
- JNJ
- STRY
- BSX
- SNY
Competitive Landscape
Zimmer Biomet faces intense competition from larger and more specialized players. Its broad portfolio is an advantage, but it must innovate to stay ahead. JNJ and Stryker tend to invest more into R&D, giving them a potential edge on new innovations.
Major Acquisitions
LDR Holding Corporation
- Year: 2016
- Acquisition Price (USD millions): 1000
- Strategic Rationale: Expanded spine portfolio and provided access to innovative spinal implant technologies.
Growth Trajectory and Initiatives
Historical Growth: Zimmer Biomet's growth has been driven by product innovation, acquisitions, and expansion into new markets. Growth has been impacted by merger integration issues and competitive pressures.
Future Projections: Analysts project modest revenue growth over the next few years, driven by demand for orthopedic procedures and new product launches. Revenue Growth Rate Estimate Next Year: Example: [0.04], EPS Growth Rate Estimate Next Year: Example: [0.06].
Recent Initiatives: Recent strategic initiatives include focusing on digital solutions, personalized medicine, and robotic-assisted surgery. Also geographic expansion into high growth markets.
Summary
Zimmer Biomet is a major player in the orthopedic device market, benefiting from a large product portfolio and global reach. However, challenges like integration complexities and intense competition exist. The company's strategic initiatives in digital solutions and robotic surgery will be crucial for future growth. Future success depends on continuing innovation and market expansion.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Investor presentations
- Analyst reports
- Industry publications
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zimmer Biomet Holdings Inc
Exchange NYSE | Headquaters Warsaw, IN, United States | ||
IPO Launch date 2001-07-25 | President, CEO & Chairman of the Board Mr. Ivan Tornos | ||
Sector Healthcare | Industry Medical Devices | Full time employees 17000 | Website https://www.zimmerbiomet.com |
Full time employees 17000 | Website https://www.zimmerbiomet.com | ||
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.